Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Celyad Oncology SA
  6. News
  7. Summary
    CYAD   BE0974260896

CELYAD ONCOLOGY SA

(CYAD)
  Report
Real-time Euronext Bruxelles  -  03:00 2022-09-28 am EDT
1.530 EUR   -5.56%
09/20Celyad Oncology to Divest Cell Therapy Facility in Belgium for $6 Million
MT
09/20Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction
BU
09/20Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CARDIO3 PROMESSES : Cardio3 BioSciences Raises EUR 23.0 million in Successful Initial Public Offering on NYSE Euronext Brussels and NYSE Euronext Paris

07/04/2013 | 01:45pm EDT

Funds to Drive Development of Unique Cell Therapy for Heart Failure

Regulatory News:

NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA

This announcement is not an offer to sell, or a solicitation of an offer to acquire any securities. This announcement is an advertisement and not a prospectus and investors should not purchase any securities referred to in this announcement except on the basis of information in the prospectus.

A prospectus was approved by the Belgian Financial Services and Markets Authority on 19 June 2013 and has been notified to the French Autorité des marchés financiers on 19 June 2013 in accordance with the European passport mechanism provided for by Directive 2003/71/CE. The prospectus may be obtained free of charge from the company upon request by email (investors@c3bs.com). The prospectus is also available on the company's website (www.c3bs.com).

Investing in the Offered Shares involves a high degree of risks. Before any investment in shares, the investor must read the "Risk Factors Section", in particular the risks relating to the description of the Company's business (from page S-6 to S-9 of the summary and from page 1 to 12 of the prospectus) and more generally, the risks relating to the shares (from page S-9 to S-10 of the summary and from page 12 to 16 of the prospectus). The Company's main assets are intellectual property rights concerning technologies that have not led to the commercialization of any product. The Company has never been profitable and it has never commercialised any products.

The biotechnology company, Cardio3 BioSciences SA (Cardio3 BioSciences) (Paris:CARD) (Brussels:CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, today announces it has successfully completed its Initial Public Offering.

The IPO was priced at ?16.65 per share. Cardio3 BioSciences will issue 1,381,500 new shares equivalent to ?23.0m including the partially exercised increase option. Additionally, an over-allotment option to subscribe to up to 207,225 additional shares at the IPO price, equivalent to ?3.45m, has been granted to Kempen & Co, on behalf of the Joint Bookrunners, for the sole purpose to cover over-allotments, if any. If the over-allotment option is exercised in full, the total amount of the capital increase will amount to ?26.45m.

The book was well covered with high quality demand from Belgium, France, UK, Scandinavia, The Netherlands and US.

Cardio3 BioSciences' shares will be listed on NYSE Euronext Brussels and NYSE Euronext Paris and conditional trading is expected to commence as of 5 July 2013 under the ticker symbol CARD. It is the first biotechnology company to be listed on both exchanges.

Kempen & Co acted as Global Coordinator and Kempen & Co and Invest Securities acted as Joint Bookrunners. Portzamparc acted as Selling Agent. Merodis acted as financial advisor to the company.

Dr Christian Homsy, CEO of Cardio3 BioSciences said: "We expect that the success of our IPO will allow us to complete our European Phase III study for C-Cure®, a unique cell therapy for the treatment of heart failure. Heart failure is a significant burden to patients, families and society in general. We believe C-Cure® has the potential to go beyond symptom relief towards healing heart tissue and could mark a significant step forward in treatment for heart failure patients. Our new funds will put us in a good position to gain approval from the FDA to begin our US study and begin clinical trials with one of our pipeline products for acute myocardial infarction (AMI) or 'heart attack'.

"We welcome our new investors, both institutional and private individuals, and look forward to advancing important new regenerative therapies for heart disease towards the market and generating value for shareholders."

Cardio3 BioSciences is developing its most advanced therapy, C-Cure®, for the treatment of heart failure, one of the world's greatest unmet medical needs. C-Cure® is a unique cell therapy aimed at repairing damaged tissue and improving heart function, clinical outcomes and quality of life. It builds on research conducted at Mayo Clinic (Rochester, Minnesota, USA), Cardio3 BioSciences and Cardiovascular Centre Aalst (Aalst, Belgium).

The supporting science is the result of Mayo Clinic innovation leading to advanced product development, manufacturing scale-up, and clinical trial execution by Cardio3 BioSciences catalyzed by ongoing collaboration facilitated through Mayo Clinic Ventures.

"Historic advances in patient care treatments, like this, come about through close collaborations between medical centers and biotechnology companies. Their combined expertise accelerates the ability to effectively get new treatments to patients," said Professor Andre Terzic, Director Mayo Clinic Center for Regenerative Medicine.

Having achieved positive Phase II results, recently published in the Journal of the American College of Cardiology (JACC) (Bartunek et al. 2013 - see below), the product is currently being tested in Europe in a Phase III trial (CHART-1). CHART-1 is the world's first phase III trial using pre-programmed cardiac progenitor cells for the treatment of heart failure.

Offering Highlights

  • The final IPO price was set at ?16.65 per share and applies to both retail and institutional investors.
  • The total number of shares that were sold amounts to 1,588,725 shares, including 81,500 shares resulting from the exercise of the increase option and 207,225 over-allotment shares.
  • Retail investors have been allocated 9.3% of the total number of allocated shares. Retail investors will be allocated 100% of their requested shares.
  • As a result of this IPO, Cardio3 BioSciences has raised ?23.0m in gross proceeds. Together with the existing shares, the number of outstanding shares (before the exercise of the over-allotment option) amounts to 6,125,567 representing a market capitalization of approximately ?102.0m based on the IPO price.
  • The shares have been listed and conditional trading is expected to commence as of 5 July 2013 on NYSE Euronext Brussels and on NYSE Euronext Paris under the symbol CARD. Delivery and payment of the shares is expected to be made on 9 July 2013.

About Cardio3 BioSciences

Cardio3 BioSciences is a leading Belgian biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007. Cardio3 BioSciences leverages research collaborations in the US and in Europe with, amongst other, Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.

The Company's lead product candidate C-Cure® is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure® consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to become new cardiac progenitor cells that behave like those cells lost to heart disease. This reprogramming process is known as Cardiopoiesis.

Cardio3 BioSciences has also developed C-Cath®ez, a technologically advanced injection catheter with superior efficiency of delivery of biotherapeutic agents into the myocardium.

Bartunek, J., A. Behfar, D. Dolatabadi, M. Vanderheyden, M. Ostojic, J. Dens, B. E. Nakadi, M. Banovic, B. Beleslin, M. Vrolix, V. Legrand, C. Vrints, J. L. Vanoverschelde, R. Crespo-Diaz, C. Homsy, M. Tendera, S. Waldman, W. Wijns and A. Terzic (2013). "Cardiopoietic stem cell therapy in heart failure The C-CURE multicenter randomized trial with lineage-specified biologics." J Am Coll Cardiol.

In accordance with the Bayh-Dole Act, Mayo Clinic has licensed the technology underlying C-Cure® to Cardio3 BioSciences and received an equity position in the company in the context of the license. Mayo Clinic and the inventors of the technology, Drs. Andre Terzic and Atta Behfar, have a financial interest associated with the technology related to this research. While no royalties have accrued to date, Mayo Clinic has rights to receive future royalties which will be shared with Drs. Terzic and Behfar in accordance with the Mayo Clinic Royalty sharing policy.

C3BS-CQR-1, C-Cure®, C-Cath, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities.

This announcement is not an offer to sell, or a solicitation of an offer to acquire any securities. This announcement is an advertisement and not a prospectus and investors should not purchase any securities referred to in this announcement except on the basis of information in the prospectus approved by the FSMA and notified to the AMF in accordance with the European passport mechanism provided for by Directive 2003/71/CE (including the risk factors relating to the Company's business (see "Summary - D1", pages S-6 to S-9 and Section 1.1 "Risks factors related to the Company's business", pages 1 to 12) and the risk factors relating to the offering (see "Summary - D3", page S-9 to S-10 and Section 1.2 "Risks factors related to the Company's shares and the Offering ", pages 12 to 16")).

Acquiring investments to which this announcement relates may expose an investor to a significant risk of losing the entire amount or part of the amount invested. Persons considering such investments should consult an authorised person specialising in advising on such investments. This announcement does not constitute a recommendation concerning the contemplated offering. The value of the shares can decrease as well as increase. Potential investors should consult a professional advisor as to the suitability of the contemplated offering for the person concerned.

This announcement is not an offer of securities in the United States. The securities to which these materials relate have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. There will be no public offering of the securities in the United States.

The Company has not authorized any offer to the public of securities in any Member State of the European Economic Area other than Belgium and France. With respect to each Member State of the European Economic Area other than Belgium and France and which has implemented the Prospectus Directive (each, a "Relevant Member State"), no action has been undertaken or will be undertaken to make an offer to the public of securities requiring a publication of a prospectus in any Relevant Member State. As a result, the securities may only be offered in a Relevant Member State to qualified investors in that Relevant Member State within the meaning of the Prospectus Directive. For the purposes of this paragraph, the expression an "offer to the public of securities" in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to purchase any securities, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State and the expression "Prospectus Directive" means Directive 2003/71/EC (as amended) and includes any relevant implementing measure in each Relevant Member State.

This announcement is being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons in (i), (ii) and (iii) above together being referred to as "relevant persons"). Any invitation, offer or agreement to subscribe, purchase or otherwise acquire securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

Cardio3 BioSciences
Dr Christian Homsy, CEO
Anne Portzenheim, Communication Manager
www.c3bs.com
Tel : +32 10 39 41 00
aportzenheim@c3bs.com
Citigate Dewe Rogerson
David Dible/Chris Gardner/Malcolm Robertson
Tel : +44 (0) 207 638 9571
david.dible@citigatedr.co.uk


© Business Wire 2013
All news about CELYAD ONCOLOGY SA
09/20Celyad Oncology to Divest Cell Therapy Facility in Belgium for $6 Million
MT
09/20Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transa..
BU
09/20Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transa..
AQ
09/20CELYAD ONCOLOGY SA : Business information
CO
09/20Cellistic emtered into asset purchase agreement to acquire Manufacturing Business Unit ..
CI
08/08Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlight..
AQ
08/05Transcript : Celyad Oncology SA, H1 2022 Earnings Call, Aug 05, 2022
CI
08/05Celyad Oncology : Reports First Half 2022 Financial Results and Recent Business Highlights..
PU
08/05Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2022
CI
08/05Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlight..
BU
More news
Analyst Recommendations on CELYAD ONCOLOGY SA
More recommendations
Financials
Sales 2022 - - -
Net income 2022 -28,2 M -27,1 M -27,1 M
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 36,6 M 35,1 M 35,1 M
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 98
Free-Float 60,2%
Chart CELYAD ONCOLOGY SA
Duration : Period :
Celyad Oncology SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELYAD ONCOLOGY SA
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,62 €
Average target price 11,00 €
Spread / Average Target 579%
EPS Revisions
Managers and Directors
Michel E. Lussier Chief Executive Officer & Executive Director
David Georges Vice President-Finance & Administration
Hilde Windels Chairman
Frederic Lehmann VP-Clinical Development & Medical Affairs
David Gilham Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
CELYAD ONCOLOGY SA-53.91%35
MODERNA, INC.-51.87%47 816
IQVIA HOLDINGS INC.-35.18%34 110
LONZA GROUP AG-41.57%33 329
SEAGEN INC.-12.45%24 963
ALNYLAM PHARMACEUTICALS, INC.16.40%24 319